CMC Biologics and IDT Biologika expand ADC manufacturing collaboration

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/Choreograph)
(Image: iStock/Choreograph)

Related tags Monoclonal antibodies

CMC Biologics and IDT Biologika have added Cerbios-Pharma SA and Oncotec Pharma Produktion GmbH to the companies’ PROVEO Partnership – a strategic collaboration for manufacturing antibody drug conjugates (ADCs).

According to the companies, with its new members the partnership will now be able to support the development and manufacture of complex ADCs from drug substance to final drug product.

PROVEO also offers project management, supply chain system, and quality systems.

As part of the partnership, CMC Biologics provides monoclonal antibody production and IDT Biologika performs analytical services, supply chain and secondary packaging through to final drug product.

Moving forward, Cerbios will carry out process development, manufacture of the cytotoxic drug-linker payload, in addition to providing conjugation services of the ADC drug substance. Oncotec will provide aseptic fill and lyophilization of the ADC drug product.

The services will be available through the PROVEO Partnership in early 2017.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us


View more